KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Current Assets (2020 - 2025)

Ginkgo Bioworks Holdings' Current Assets history spans 6 years, with the latest figure at $471.8 million for Q4 2025.

  • For Q4 2025, Current Assets fell 21.72% year-over-year to $471.8 million; the TTM value through Dec 2025 reached $471.8 million, down 21.72%, while the annual FY2025 figure was $471.8 million, 21.72% down from the prior year.
  • Current Assets reached $471.8 million in Q4 2025 per DNA's latest filing, down from $506.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.8 billion in Q3 2021 to a low of $966879.0 in Q2 2021.
  • Average Current Assets over 5 years is $973.3 million, with a median of $952.4 million recorded in 2023.
  • Peak YoY movement for Current Assets: soared 165261.75% in 2022, then crashed 41.98% in 2024.
  • A 5-year view of Current Assets shows it stood at $1.7 billion in 2021, then dropped by 15.84% to $1.5 billion in 2022, then tumbled by 30.92% to $1.0 billion in 2023, then tumbled by 39.83% to $602.7 million in 2024, then decreased by 21.72% to $471.8 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Current Assets are $471.8 million (Q4 2025), $506.1 million (Q3 2025), and $523.0 million (Q2 2025).